Frost & Sullivan: By 2035, there will be 74.4 million couples in China experiencing infertility.

On March 21, the globally renowned consulting firm Frost & Sullivan released the “2026 White Paper on the Development Status and Future Trends of the Assisted Reproductive Industry in China.”

The white paper shows that in recent years, the incidence of infertility in China has remained at a high level. In 2023, the infertility rate in China is approximately 18.2%. It is expected that the number of infertile couples in China will increase year by year, rising from 54.8 million pairs in 2020 to 60.6 million pairs in 2025, and further increasing to 74.4 million pairs by 2035. The disease burden of infertility continues to grow, and the demand for assisted reproduction is further enhanced.



The white paper indicates that in recent years, driven by policy support and the growing demand for infertility treatment, the number of licensed assisted reproductive institutions in China has been steadily increasing. In 2020, there were 536 assisted reproductive centers in mainland China, of which 78 institutions performed third-generation preimplantation genetic testing (PGT).

The number of egg retrieval cycles is an important indicator for measuring the scale and service capacity of assisted reproductive institutions. In recent years, the number of egg retrieval cycles for in vitro fertilization in China has been continuously increasing. The number of nationwide egg retrieval cycles was 611,000 in 2020, and it is expected to grow to 1,001,000 by 2025. With the improvement of technology and the growth in patient demand, it is expected that by 2035, the number of egg retrieval cycles in China will reach 1,885,000.



The global market size for assisted reproductive services continues to grow. In 2020, the market size was approximately $26 billion, and it is expected to increase to $38.9 billion by 2025. From 2020 to 2030, driven by the rising proportion of infertility among older individuals and increased treatment penetration, the assisted reproductive market in China is in a phase of demand release, with the market size growing from 23.5 billion yuan to 63 billion yuan. After 2030, the market will gradually enter a stable development phase, with an expected growth to 86.5 billion yuan by 2035.